The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1686
October 2, 2023
View Complete Issue         Table of Contents 2019 
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
October 2, 2023 (Issue: 1686)
Colchicine (Colcrys, and others), which has been available in the US for decades for prophylaxis and treatment of gout flares and other indications in oral formulations that contain 0.6 mg of the drug, has now been approved in 0.5-mg tablets...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
Article code: 1686b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.